GEMCITABINE IN PATIENTS WITH ABNORMAL LIVER AND RENAL FUNCTION

吉西他滨治疗肝肾功能异常患者

• 批准号: 6245891
• 负责人: GERALD H CLAMON
• 金额: $ 1.92万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-01 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245891
• 关键词: antimetabolites; clinical research; dosage; drug screening /evaluation; enzyme inhibitors; human subject; human therapy evaluation; kidney disorder; liver disorder; neoplasm /cancer chemotherapy; pharmacokinetics; ribonucleotide reductase

The goal of the study is to determine the maximum tolerated dose of gemcitabine in cancer patients who have liver or renal dysfunction and to correlate toxicity with gemcitabine pharmacokinetic parameters of Cmax and AUC.

该研究的目标是确定最大耐受量 吉西他滨治疗有肝肾功能障碍的癌症患者 吉西他滨药物动力学参数与毒性的相关性 和AUC。